Hyperglycemic Hyperosmolar Syndrome
Clinical Pathways promote evidence based, safe, and high-value care for patients by providing clinical recommendations and standard processes. They are developed by multidisciplinary committees of subject matter experts, informed by methodical review of available evidence and consensus among committee members.
Clinical Pathways:
- Diabetic ketoacidosis (DKA) vs. hyperglycemic hyperosmolar syndrome (HHS) Algorithm
- PICU HHS Algorithm
- Hyperglycemic Hyperosmolar Syndrome (HHS) synopsis (provides care standards employed for this clinical pathway)
Inclusion criteria:
- Severe hyperglycemia (glucose > 500)
- Effective serum osmolality > 350
- Serum bicarbonate > 16 mmol/L
Committee members involved in the development:
- M. Knoll, MD, MHPE | Endocrinology | Committee chair
- T. Musick, DO | Endocrinology | Committee member
- R. McDonough, DO | Endocrinology | Committee member
- A. Stoner, MS, DO | Critical Care Medicine | Committee member
- S. Fagan, RN, BSN, CCRN-K | Pediatric Intensive Care Unit | Committee member
EBP Committee Members:
- K. Berg, MD, FAAP | Hospitalist, Evidence Based Practice
- Megan Gripka, MT (ASCP) SM | Evidence Based Practice
Publication dates:
- Finalized date: 12/2024
- Next expected revision date: 12/2027
If you have any questions regarding this content or identify a broken link, please email evidencebasedpractice@cmh.edu.
These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.